China's First "Ankylosing Spondylitis Standardized Medical Center (ASSC)" Project Launched, Marking a New Level of Diagnosis and Treatment Management of Ankylosing Spondylitis (AS)
Taken from: Wanbang Biopharma
On November 22, 2020, the first "Ankylosing Spondylitis Standardized Medical Center (ASSC)" project in China, sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), China Rheumatology Data Center (CRDC) and Chinese Rheumatology Center Alliance (CRCA) and co-sponsored by Wanbang Biopharma, was officially launched at the meeting of Chinese Rheumatology Center Alliance. The Ankylosing Spondylitis Standardized Medical Center is committed to providing those patients with specialized management services in terms of patient education, diagnosis and treatment, and professional HCCM service, and building a comprehensive education and training platform integrating clinical, teaching and scientific research for medical staff, which marks a new development of standardized diagnosis and treatment of important diseases in the field of rheumatism in China!
Professor Zeng Xiaofeng (Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Zhao Yan (Committee Chairman of Chinese Rheumatology Association of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Huang Cibo (Vice Committee Chairman of Chinese Rheumatology Association of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Beijing Hospital), Professor Zhang Zhiyi (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Immunology of the First Affiliated Hospital of Harbin Medical University), Professor Liu Yi (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Immunology, West China Hospital), Professor Zhang Zhuoli (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Association, Doctor of Rheumatology and Clinical Immunology Department of Peking University First Hospital), Professor Li Mengtao (Vice Chairman of Rheumatology Branch of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Su Yin (Committee Chairman-designate of the Rheumatology Branch of Beijing Medical Association, Doctor of the Department of Rheumatology and Immunology of Peking University People's Hospital), and Mr. Yuan Chun (co-president of Jiangsu Wanbang Pharmaceutical Marketing & Distribution Co., Ltd.) jointly congratulated on the launch of the project.
Professor Zeng Xiaofeng, President of the Rheumatology and Immunology Branch of the Chinese Medical Doctor Association, pointed out at the meeting — "At present, many tertiary hospitals do not have a special rheumatology and immunology department, but early diagnosis, early standardized treatment and systematic chronic disease management are crucial for patients. It is imperative to strengthen discipline construction. The Ankylosing Spondylitis Standardized Medical Center project can not only provide high-quality services for one-stop diagnosis and treatment and HCCM service for patients, but also promote academic exchanges and cooperation in the field of rheumatology in China as well as the development of the discipline."
According to the epidemiology survey, it takes an average of 6 years for patients with ankylosing spondylitis in China from the first onset of symptoms to the first definite diagnosis by a doctor. At the same time, ankylosing spondylitis also has the characteristics of high recurrence rate and high disability rate; it is also a widespread problem that long-term drug medication causes heavy economic burden on patients. In view of the current series of practical problems in front of patients, Mr. Yuan Chun, co-president of Jiangsu Wanbang Pharmaceutical Marketing & Distribution Co., Ltd., said that "Rheumatic immunity is one of the main therapeutic areas where Wanbang Biopharma focuses on. Targeting the unmet needs of patients, we have always tried to innovate and are committed to not only providing patients with "high-quality and affordable" products, but also providing medical personnel with HCCM solutions. The launch of Ankylosing Spondylitis Standardized Medical Center project will surely contribute to the improvement of China's disease management capacity for ankylosing spondylitis, help medical development and benefit more patients."
Gather national strength to build a standardized diagnosis and treatment system for ankylosing spondylitis
The Ankylosing Spondylitis Standardized Diagnosis and Treatment Center (ASSC) Project adheres to the principle of "scientific, joint development and sharing", and plans to co-operate with 1,000 hospitals in the next three years. At the same time, the Center will set up a special support plan to provide supports in terms of infrastructure and service, scientific research project and cooperation project for the members. Under the guidance of the ASSC Expert Committee, the specialists in the hospitals joining this project will receive various learning and improvement opportunities such as remote ward round teaching, support from health poverty relief projects, and national academic training. ASSC will provide the hospitals with a comprehensive patient management system, conduct long-term follow-up of AS patients and establish big data research data, and all project participants have the right to use the data to conduct clinical researches. The project centers that meet the requirements will be given the certification qualification of "Ankylosing Spondylitis Standardized Medical Center" or "Excellent Ankylosing Spondylitis Standardized Medical Center" by CRDC, CRCA and NCRC.
Welcome to sign up for the project
On November 22, 2020, the first "Ankylosing Spondylitis Standardized Medical Center (ASSC)" project in China, sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), China Rheumatology Data Center (CRDC) and Chinese Rheumatology Center Alliance (CRCA) and co-sponsored by Wanbang Biopharma, was officially launched at the meeting of Chinese Rheumatology Center Alliance. The Ankylosing Spondylitis Standardized Medical Center is committed to providing those patients with specialized management services in terms of patient education, diagnosis and treatment, and professional HCCM service, and building a comprehensive education and training platform integrating clinical, teaching and scientific research for medical staff, which marks a new development of standardized diagnosis and treatment of important diseases in the field of rheumatism in China!
Professor Zeng Xiaofeng (Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Zhao Yan (Committee Chairman of Chinese Rheumatology Association of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Huang Cibo (Vice Committee Chairman of Chinese Rheumatology Association of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Beijing Hospital), Professor Zhang Zhiyi (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Immunology of the First Affiliated Hospital of Harbin Medical University), Professor Liu Yi (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Doctor Association, Doctor of Department of Rheumatology and Immunology, West China Hospital), Professor Zhang Zhuoli (Vice Chairman of Rheumatology and Immunology Branch of Chinese Medical Association, Doctor of Rheumatology and Clinical Immunology Department of Peking University First Hospital), Professor Li Mengtao (Vice Chairman of Rheumatology Branch of Chinese Medical Association, Doctor of Department of Rheumatology and Clinical Immunology of Peking Union Medical College Hospital), Professor Su Yin (Committee Chairman-designate of the Rheumatology Branch of Beijing Medical Association, Doctor of the Department of Rheumatology and Immunology of Peking University People's Hospital), and Mr. Yuan Chun (co-president of Jiangsu Wanbang Pharmaceutical Marketing & Distribution Co., Ltd.) jointly congratulated on the launch of the project.
Professor Zeng Xiaofeng, President of the Rheumatology and Immunology Branch of the Chinese Medical Doctor Association, pointed out at the meeting — "At present, many tertiary hospitals do not have a special rheumatology and immunology department, but early diagnosis, early standardized treatment and systematic chronic disease management are crucial for patients. It is imperative to strengthen discipline construction. The Ankylosing Spondylitis Standardized Medical Center project can not only provide high-quality services for one-stop diagnosis and treatment and HCCM service for patients, but also promote academic exchanges and cooperation in the field of rheumatology in China as well as the development of the discipline."
According to the epidemiology survey, it takes an average of 6 years for patients with ankylosing spondylitis in China from the first onset of symptoms to the first definite diagnosis by a doctor. At the same time, ankylosing spondylitis also has the characteristics of high recurrence rate and high disability rate; it is also a widespread problem that long-term drug medication causes heavy economic burden on patients. In view of the current series of practical problems in front of patients, Mr. Yuan Chun, co-president of Jiangsu Wanbang Pharmaceutical Marketing & Distribution Co., Ltd., said that "Rheumatic immunity is one of the main therapeutic areas where Wanbang Biopharma focuses on. Targeting the unmet needs of patients, we have always tried to innovate and are committed to not only providing patients with "high-quality and affordable" products, but also providing medical personnel with HCCM solutions. The launch of Ankylosing Spondylitis Standardized Medical Center project will surely contribute to the improvement of China's disease management capacity for ankylosing spondylitis, help medical development and benefit more patients."
Gather national strength to build a standardized diagnosis and treatment system for ankylosing spondylitis
The Ankylosing Spondylitis Standardized Diagnosis and Treatment Center (ASSC) Project adheres to the principle of "scientific, joint development and sharing", and plans to co-operate with 1,000 hospitals in the next three years. At the same time, the Center will set up a special support plan to provide supports in terms of infrastructure and service, scientific research project and cooperation project for the members. Under the guidance of the ASSC Expert Committee, the specialists in the hospitals joining this project will receive various learning and improvement opportunities such as remote ward round teaching, support from health poverty relief projects, and national academic training. ASSC will provide the hospitals with a comprehensive patient management system, conduct long-term follow-up of AS patients and establish big data research data, and all project participants have the right to use the data to conduct clinical researches. The project centers that meet the requirements will be given the certification qualification of "Ankylosing Spondylitis Standardized Medical Center" or "Excellent Ankylosing Spondylitis Standardized Medical Center" by CRDC, CRCA and NCRC.
Welcome to sign up for the project
The sign-up channel is about to open. Please scan the QR code below to follow the [Official WeChat Account] to register, and learn about the development history, expert committee, certification application process and training and learning of the Center.
Previous：Building a Malaria-free World: Fosun Pharma Working with World-renowned Malaria Experts to Explore New Trends in Malaria Prevention in Children and Pregnant Women
Next：Recognized Again! Henlius Publishes Phase 1 Clinical Study Results on HAN QU YOU®in International Journal Cancer Chemotherapy and Pharmacology